Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Cai, Qingxian; Yang, Minghui; Liu, Dongjing; Chen, Jun; Shu, Dan; Xia, Junxia; Liao, Xuejiao; Gu, Yuanbo; Cai, Qiue; Yang, Yang; Shen, Chenguang; Li, Xiaohe; Peng, Ling; Huang, Deliang; Zhang, Jing; Zhang, Shurong; Wang, Fuxiang; Liu, Jiaye; Chen, Li; Chen, Shuyan; Wang, Zhaoqin; Zhang, Zheng; Cao, Ruiyuan; Zhong, Wu; Liu, Yingxia; Liu, Lei

doi:10.1016/j.eng.2020.03.007

Public

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Published in Engineering • Mar 18, 2020

Authors:

Qingxian Cai

Minghui Yang

Dongjing Liu

Abstract

There is currently an outbreak of respiratory disease caused by a novel coronavirus . The virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes has been named coronavirus disease 2019 (COVID-19). More than 16% of patients developed acute respirat...

Subject

Favipiravir

Coronavirus disease 2019 (COVID-19)

Virology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!